NPS rolling with NDA, but stock takes beating in frightened market
This article was originally published in Scrip
Executive Summary
NPS Pharmaceuticals submitted the chemistry, manufacturing and controls (CMC) section of its rolling new drug application (NDA) to the US FDA for Gattex (teduglutide), a recombinant analogue of human glucagon-like peptide 2.